ClinicalTrials.gg
CompletedNCT05772299Updated Oct 10, 2023

Treatment of Inflammation Around Implants With a Laser or an Ultrasonic Device

An interventional study of Er:Yag laser and EMS ultrasound in Peri-implant Mucositis, sponsored by Kristianstad University. Completed at 1 site in Sweden. Open to participants aged 23 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Kristianstad University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Aug 2021, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
23 Years to 100 Years
Sex
All
01

Study summary

The goal of the clinical trial is to compare laser therapy with ultrasonic therapy in patients with inflammation in the tissue surrounding single implants (peri-implant mucositis). The outcomes are bleeding on probing (BOP), pocket depth, suppuration, recession of the peri-implant mucosal margin, the treatment time and changes in bone levels before and after treatment in the test, and control group respectively. The quality of life will be measured from a standardized protocol.

The hypothesis is that treatment with laser therapy in patients with peri-implant mucositis will show less inflammation with less bleeding and a better pocket closure compared to the treatment with the ultrasound.

Read the detailed description

Data from the clinical treatment will be registered in medical records. In parallel, clinical data will be documented in a study protocol and saved in a safe together with a code list in accordance with a standard operation procedure at the clinic.The protocol with the specific treatment procedure (test or control) will not be opened until the study is completed and only by authorized persons with access to the data in the study such as, the principal investigator and the statisticians.

Variables used in the study originates from an international world workshop on the classification of periodontal and peri-implant diseases and conditions in 2018. In accordance with the working group a diagnosis of peri-implant mucositis should include bleeding on probing and or pus and no bone loss (X-ray). In this study the primary outcomes are bleeding on probing (BOP) and or pus and pocket depth,

The aim is to assess the clinical outcome over 6 months following treatment with non-surgical debridement using an Er:Yag laser device (AdvErL EVO, Morita corporation, Japan) (Test group) or with the use of mechanical therapy using an ultrasonic device with a specially designed tip (EMS, Switzerland) (Control group). An active comparator (Control group) was compared to an experimental arm (Test group).

Patients will therefore be randomized into a test or control group. Inclusion criteria will follow a full mouth routine periodontal examination, including analysis of available radiographs.

All measurements will be performed by a dental hygienist who is blinded for the specific treatment test or control. A periodontist will perform all the treatments and is therefore not blinded. Upon the final appointment the specific arm of treatment will be registered by the periodontist in the patient journal.

All patients will be given oral and written information about the study and sign a written informed consent. The patients will be informed that they could drop off whenever they want without any explanations. The ethical board approved the study.

The test group will be treated using the Er:Yag laser device.The control group will be treated using an ultrasonic device with peek coated tips (EMS, Switzerland). Following treatment all patients, independent of group, will be instructed in proper home care using a toothbrush and interproximal aids as needed.

Study design:

  • Baseline: Clinical registrations and treatment
  • 1 month: Clinical registrations
  • 3 months: Clinical registrations and treatment
  • 6 months: Clinical registrations and treatment

In addition, the instrument Oral Health Impact Profile (OHIP) will be used as a measurement of quality of life.

Adverse events will be evaluated at each visit. If a patient should require any treatment during the study the necessary treatment will be provided and according to the standard of care. If adverse events related to the treatment they will be recorded. The investigation will be performed according to the principles of the Declaration of Helsinki on experimentation involving human subjects.

Participant not fulfilling the study will be reported in the patient journal as not completed and statistically noted as missing data.

From the statistical power analysis 38 individuals were minimum to reach a clinically significant difference. The power analysis was based on: if bleeding on probing (BOP) is reduced with 30% ± 10 in the test group and with a 30% decrease in the control group is to be detected at alpha =0.05 and a power of beta= 0.2. Hence it is foreseen to incorporate 45 subjects in the study if some of the individuals will not fulfil the study.

The IBM SPSS version 28.0 statistical software package (SPSS Inc., Armonk, NY, USA) for personal computer will be used in the statistical analyses.

Statistics will be calculated as means with standard deviation (SD). Independent t-tests (equal variance not assumed) paired t-test and one-way ANOVA test will be used to compare inter and intra-group differences. Non-parametric chi-square test will be used for categorical variables. Statistical significance will be set with 80 percent at p \< 0.05. Non visits will be recorded as missing data in the statistics.

02

Conditions studied

  • Peri-implant Mucositis

Browse trials for

Keywords

  • Clinical study
  • Bleeding on probing
  • Pus
  • Er:Yag laser
  • Ultrasonic device
03

In context

Suppuration

8 studies on the registry are indexed under Suppuration; 1 is open to participants now.

Browse Suppuration studies →

Lead sponsor

Kristianstad University is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
23 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 1 peri-implant site with probing depth ≥ 4 mm combined with bleeding and or pus on probing
  • bone loss ≤ 2 mm measured from the implant shoulder (as a consequence of remodelling during the healing process)

Exclusion criteria

Exclusion Criteria:

  • Subjects with uncontrolled diabetes >6.5
  • Subjects requiring prophylactic antibiotics
  • Subjects taking prednisolone
  • Subjects taking medications known to have effects on gingival overgrowth
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Er:Yag laser treatment

    The experimental (test) group will receive the following treatment: The submucosal debridement will be performed with an Er:Yag laser (AdvErL EVO, Morita Corporation, Japan). The P-400 tip is placed into the peri-implant mucositis pockets mesially, lingually, distally and buccally while rinsing water. Careful attempts are to cover the full circumference of the implant.

    Radiation: Er:Yag laser

  • Active comparator
    Ultrasonic device treatment

    The active comparator (control) group will receive the following treatment: The submucosal debridement will be performed by a piezoelectric ultrasonic device with a PEEK coated tip (EMS, Switzerland). The tip is placed into the peri-implant mucositis pockets mesially, lingually, distally and buccally while rinsing water. Careful attempts are to cover the full circumference of the implant.

    Device: EMS ultrasound

Interventions

  • RadiationEr:Yag laser

    Submucosal debridement is performed with Er:Yag laser using a P-400 tip under rinsing water.

  • DeviceEMS ultrasound

    Submucosal debridement is performed with piezoelectric ultrasound (EMS) with a PEEK (plastic coated) tip under rinsing water.

06

What researchers measure

Primary outcomes

  1. Bleeding on probing (BOP)

    millimeter

    Time frame: Baseline

  2. Bleeding on probing (BOP)

    millimeter

    Time frame: 1 month

  3. Bleeding on probing (BOP)

    millimeter

    Time frame: 3 months

  4. Bleeding on probing (BOP)

    millimeter

    Time frame: 6 months

  5. Probing pocket depth (PPD)

    millimeter

    Time frame: Baseline

  6. Probing pocket depth (PPD)

    millimeter

    Time frame: 1 month

  7. Probing pocket depth (PPD)

    millimeter

    Time frame: 3 months

  8. Probing pocket depth (PPD)

    millimeter

    Time frame: 6 months

  9. Pus

    Presence or abscence

    Time frame: Baseline

  10. Pus

    Presence or abscence

    Time frame: 1 month

  11. Pus

    Presence or abscence

    Time frame: 3 months

  12. Pus

    Presence or abscence

    Time frame: 6 months

Secondary outcomes

  1. Recession of the peri-implant mucosal margin

    millimeter

    Time frame: Baseline

  2. Recession of the peri-implant mucosal margin

    millimeter

    Time frame: 6 months

  3. Bone level (peri-apical radiographs)

    millimeter on Xray

    Time frame: Baseline

  4. Bone level (peri-apical radiographs)

    millimeter on Xray

    Time frame: 6 months

  5. Implant loss

    Prevalence

    Time frame: Baseline

  6. Implant loss

    Prevalence

    Time frame: 1 month

  7. Implant loss

    Prevalence

    Time frame: 3 months

  8. Implant loss

    Prevalence

    Time frame: 6 months

  9. Treatment time

    minutes

    Time frame: Baseline

  10. Treatment time

    minutes

    Time frame: 3 months

  11. Treatment time

    minutes

    Time frame: 6 months

  12. Quality of life (QoL)

    Questionnaire "Oral Health Impact Proflie" (OHIP-14) on a 5 -point Likert scale 0=never (best) ; 5=very often (worst)

    Time frame: Baseline

  13. Quality of life (QoL)

    Questionnaire "Oral Health Impact Profile" (OHIP-14) on a 5 -point Likert scale 0=never (best) ; 5=very often (worst)

    Time frame: 6 months

07

Study locations

1 site
  • University of Kristianstad
    Kristianstad, 29893, Sweden
08

References and documents

Publications

  • Aoki A, Sasaki KM, Watanabe H, Ishikawa I. Lasers in nonsurgical periodontal therapy. Periodontol 2000. 2004;36:59-97. doi: 10.1111/j.1600-0757.2004.03679.x. No abstract available. PubMed 15330944 ↗
  • Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, Chen S, Cochran D, Derks J, Figuero E, Hammerle CHF, Heitz-Mayfield LJA, Huynh-Ba G, Iacono V, Koo KT, Lambert F, McCauley L, Quirynen M, Renvert S, Salvi GE, Schwarz F, Tarnow D, Tomasi C, Wang HL, Zitzmann N. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018 Jun;45 Suppl 20:S286-S291. doi: 10.1111/jcpe.12957. PubMed 29926491 ↗
  • Derks J, Tomasi C. Peri-implant health and disease. A systematic review of current epidemiology. J Clin Periodontol. 2015 Apr;42 Suppl 16:S158-71. doi: 10.1111/jcpe.12334. PubMed 25495683 ↗
  • Lin GH, Suarez Lopez Del Amo F, Wang HL. Laser therapy for treatment of peri-implant mucositis and peri-implantitis: An American Academy of Periodontology best evidence review. J Periodontol. 2018 Jul;89(7):766-782. doi: 10.1902/jop.2017.160483. PubMed 30133748 ↗
  • Renvert S, Lessem J, Dahlen G, Lindahl C, Svensson M. Topical minocycline microspheres versus topical chlorhexidine gel as an adjunct to mechanical debridement of incipient peri-implant infections: a randomized clinical trial. J Clin Periodontol. 2006 May;33(5):362-9. doi: 10.1111/j.1600-051X.2006.00919.x. PubMed 16634959 ↗
  • Renvert S, Persson GR, Pirih FQ, Camargo PM. Peri-implant health, peri-implant mucositis, and peri-implantitis: Case definitions and diagnostic considerations. J Periodontol. 2018 Jun;89 Suppl 1:S304-S312. doi: 10.1002/JPER.17-0588. PubMed 29926953 ↗
  • Takasaki AA, Aoki A, Mizutani K, Kikuchi S, Oda S, Ishikawa I. Er:YAG laser therapy for peri-implant infection: a histological study. Lasers Med Sci. 2007 Sep;22(3):143-57. doi: 10.1007/s10103-006-0430-x. Epub 2007 Jan 12. PubMed 17219255 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Aug 2023, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
Mar 16, 2023
StartActual
Aug 31, 2021
Primary completionActual
Aug 17, 2023
CompletionActual
Aug 17, 2023
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05772299
Lead sponsor
Kristianstad University
Responsible party
Viveca Wallin Bengtsson (Principle investigator, Kristianstad University) — Principal investigator
First posted
Mar 16, 2023
Start date
Aug 31, 2021
Primary completion
Aug 17, 2023
Completion
Aug 17, 2023
Last update
Oct 10, 2023

Study contacts

Stefan Renvert, Prof
principal investigator · Kristianstad University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion